<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        47-249-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MASTASONE 0.05% NASAL SPRAY
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOMETASONE FUROATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Nasal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Nasal spray, suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R01AD09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MASTASONE is a corticosteroid, which reduces inflammation. It was prescribed to you by your doctor to treat the symptoms of one of the following conditions:</p><p><strong>In adults, adolescents and children between the ages of 3 and 11 years:</strong></p><p><strong><em>Seasonal allergic rhinitis:</em></strong><br />Also called &ldquo;hay fever&rdquo; is caused by allergies to grass, pollen, ragweed, etc. Symptoms include stuffiness/congestion in the nose, runny nose, itching and sneezing.</p><p><em><strong>Perennial allergic rhinitis:&nbsp;</strong></em><br />Year-round allergies caused by dust mites, animal dander and molds. Symptoms include stuffiness/congestion in the nose, runny nose, itching and sneezing.</p><p><strong>In adults and children 12 years of age or older:&nbsp;</strong></p><p><em><strong>Adjunctive treatment to antibiotics in acute episodes of rhinosinusitis, where signs or symptoms of bacterial infection are present:&nbsp;</strong></em><br />Acute rhinosinusitis is the inflammation of the nasal sinuses that may be complicated with a bacterial infection. MASTASONE is used for the treatment of the inflammatory component and the antibiotic is used for the infection of the nasal sinuses. Symptoms include (but are not limited to) stuffiness/congestion in the nose, runny nose, feeling of something running down the back of the throat, fever, severe facial/tooth pain (especially on one side of the face), facial swelling or thick nasal discharge with a yellow or green colour.</p><p><em><strong>Mild to Moderate uncomplicated acute rhinosinusitis, where signs or symptoms of bacterial infection are not present:</strong></em><br />MASTASONE is used for the treatment of symptoms related to the inflammation and blockage of the sinuses behind the nose. Symptoms include stuffiness/congestion in the nose, runny nose, feeling of something running down the back of the throat, and facial pressure or pain. If symptoms get worse or you start to have fever, persistent severe facial/tooth pain (especially on one side of the face), facial swelling or thick nasal discharge with a yellow or green colour, consult your physician immediately.</p><p><strong>In adults 18 years of age or older:<br /><em>Nasal polyps:&nbsp;</em></strong><br />Small growths on the lining of the nose that usually affect both nostrils. The main symptom is a blocked feeling in the nose which may affect breathing through the nose. Other symptoms may include watery nose, a feeling of something running down the back of the throat, loss of taste and smell.</p><p><u><strong>What it does:</strong></u><br />When sprayed into the nose it helps reduce symptoms of the conditions listed above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- Do not use MASTASONE</strong></u></p><ul><li>if you are allergic to MASTASONE or to any of its ingredients.</li><li>if you have an infection in the nose (i.e. yellow or green discharge from the nose) that is not being treated.</li><li>if your nose was recently operated on or injured. In this case you may be told to wait until healing has occurred before using MASTASONE.</li><li>if you have been diagnosed with tuberculosis and it is not being treated.*</li><li>if you have untreated fungal, bacterial, or systemic viral infections.*</li><li>if you have a herpes simplex (virus) infection of the eye and it is not being treated. *</li></ul><p>* See <u><strong>Take special care with MASTASONE</strong></u> for additional information.</p><p>&nbsp;</p><p><u><strong>b- Take special care with MASTASONE</strong></u><br />Do not spray MASTASONE into your eyes or mouth. It is for use in the nose only.</p><p>Before you use MASTASONE talk to your doctor or pharmacist if you are pregnant or nursing a baby. Breast-feeding is not recommended during treatment with MASTASONE.</p><p>Tell your doctor, if you have any of the following conditions before you start using MASTASONE or develop them during treatment. Your doctor may need to lower your dose of this medication, or you may need extra treatment to control the condition. Once advised, your doctor will decide whether any changes in your treatment are needed. In some cases it may be necessary to stop treatment:</p><ul><li>sores in the nose</li><li>tuberculosis (active or previous)</li><li>infection (fungal, bacterial or viral)</li><li>herpes simplex (virus) infection of the eye</li></ul><p>(See <u><strong>do not use MASTASONE</strong></u> for additional information).</p><p>If you think you have developed an infection in the nose after starting MASTASONE (i.e. normally clear discharge from the nose has turned yellow or green) contact your doctor.</p><p>If you have been prescribed MASTASONE (but not with antibiotics) for mild-moderate uncomplicated acute rhinosinusitis, consult your doctor if you develop signs or symptoms of bacterial infection (such as fever, persistent severe facial/tooth pain (especially on one side of the face), facial swelling, worsening of symptoms after an initial improvement) or thick nasal discharge with a yellow or green colour.</p><p>Be sure to use this medicine exactly as your doctor or pharmacist has instructed. Do not use more MASTASONE than prescribed in an attempt to increase its effectiveness, and do not use this medicine more often than prescribed. Only a physician can prescribe MASTASONE for you. Do not share this medicine with anyone else; it may harm them even if their symptoms are the same as yours. Do not use this product for other disorders.</p><p>&nbsp;</p><p><u><strong>c- Taking MASTASONE with other medicines, herbal or dietary supplements</strong></u><br />To avoid the possibility of drug interactions, be sure to advise your physician or pharmacist of any other medications that you are taking, particularly corticosteroid medicine, either by mouth or by injection. The dose of some medications may need adjustment while you are treated with MASTASONE.</p><p>Drugs that may interact with MASTASONE include:</p><ul><li>Ketoconazole</li></ul><p>&nbsp;</p><p><u><strong>Drug testing for sports events&nbsp;</strong></u></p><p>This product is a corticosteroid for nasal administration. Although it is not measurable in the blood, corticosteroids may be detected in the urine during drug testing. Thus, prior written permission for its use may be required by sports agencies.</p><p>&nbsp;</p><p><u><strong>d- Taking MASTASONE with food and drink</strong></u><br />Food/meals have no influence.</p><p>&nbsp;</p><p><u><strong>e- Pregnancy and breast-feeding</strong></u><br />As with other nasal corticosteroid preparations, MASTASONE should be used in pregnant women, nursing mothers or women of childbearing age only if the potential benefit justifies the potential risk to the mother, fetus, or infant. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.</p><p>&nbsp;</p><p><u><strong>f- Driving and using machines</strong></u><br />No or negligible influence.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DO NOT SPRAY INTO EYES; FOR INTRANASAL USE ONLY.</strong></p><p>&nbsp;</p><p><u><strong>How much MASTASONE to use</strong></u><br />In case of severe nasal congestion, your doctor may recommend the use of a nasal decongestant (vasoconstrictor) 2-3 days before MASTASONE to help clear nasal passages and to aid drug delivery.</p><p>&nbsp;</p><p><strong>Treatment of seasonal or perennial allergic rhinitis:</strong></p><ul><li>For children between the ages of 3 and 11 years the usual recommended dose is one (1) spray in each nostril once a day. Young children should be aided by an adult when using MASTASONE.</li><li>For adults (including the elderly) and children 12 years of age and older, the usual recommended dose is two (2) sprays into each nostril once a day. When your symptoms are under control, your physician may recommend one (1) spray into each nostril once daily to maintain control of your symptoms.</li></ul><p>Your physician may change this dosage, depending on your response to MASTASONE.<br />&nbsp;</p><p>In some patients, MASTASONE may relieve symptoms within 12 hours; others may have to wait at least 48 hours. Full effect depends on regular and continued use (unlike other medications which are used only when necessary). For full benefit of therapy, continue regular use.</p><p>&nbsp;</p><p><strong>Adjunctive treatment to antibiotics in acute episodes of rhinosinusitis:</strong><br />For adults (including the elderly) and children 12 years of age and older, the usual recommended dose is two (2) sprays into each nostril twice a day. If needed for better control of your symptoms, your doctor may recommend that the dose be increased to four (4) sprays into each nostril twice daily.<br />Your physician may change this dosage, depending on your response to MASTASONE.</p><p>&nbsp;</p><p><strong>Treatment of mild to moderate uncomplicated acute rhinosinusitis:</strong><br />For adults (including the elderly) and children 12 years of age and older, the usual recommended dose is two (2) sprays into each nostril twice a day.<br />Contact your doctor if symptoms worsen during treatment (see TAKE SPECIAL CARE WITH MASTASONE).</p><p>&nbsp;</p><p><strong>Treatment of Nasal Polyps:</strong><br />For adults 18 years and older (including the elderly), the usual recommended dose is two (2) sprays into each nostril twice a day. Once symptoms are controlled, your physician may reduce your dose to two sprays in each nostril once daily.</p><p>&nbsp;</p><p><u><strong>How to use MASTASONE</strong></u><br /><strong>Read complete instructions carefully and use only as directed. SHAKE WELL BEFORE EACH USE.</strong></p><ol><li>Remove the plastic dust cap.&nbsp;<img alt="" width="46" height="46" src="data:image/jpeg;base64,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" /></li><li>The very first time the spray is used; prime the pump by pressing downward on the shoulders of the white applicator, using your forefinger and middle finger while supporting the base of the bottle with your thumb. Press down and release the pump ten (10) times or until a fine spray appears. The pump is now ready to use. The pump may be stored unused for up to 2 weeks without repriming. If unused for more than 2 weeks, prime the pump again two (2) times, until a fine spray appears. Gently blow&nbsp; your nose to clear your nostrils. Close one&nbsp; nostril using your finger. Tilt your head forward&nbsp; slightly and, keeping the bottle upright, carefully insert the nasal applicator into the other nostril.&nbsp;<img alt="" width="46" height="46" src="data:image/jpeg;base64,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" /></li><li>For each spray, press firmly downward once on the shoulder of the white applicator, using your forefinger and middle finger while supporting the base of the bottle with your thumb. Spray while breathing gently inward through the nostril, with the mouth closed.&nbsp;<img alt="" width="47" height="46" src="data:image/jpeg;base64,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" /><img alt="" width="46" height="45" src="data:image/jpeg;base64,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" /></li><li>Then breathe out through your mouth.&nbsp;<img alt="" width="46" height="46" src="data:image/jpeg;base64,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" /></li><li>Repeat in the other nostril.</li><li>Replace the plastic dust cap after each use.</li></ol><p>The correct amount of medication in each spray can only be assured up to 140 sprays from the bottle even though the bottle may not be completely empty. You should keep track of the number of sprays used from each bottle of MASTASONE, and discard the bottle after using 140 sprays (approximately five weeks of supply, depending on the prescribed dose).</p><p><strong>Cleaning:</strong> To clean the nasal applicator, remove the plastic dust cap and pull gently upward on the white nasal applicator so that it comes free. Wash the applicator and dust cap under a cold-water tap. <strong>Do not try to unblock the nasal applicator by inserting a pin or other sharp object as this will damage the applicator and cause you not to get the right dose of medicine.</strong> Dry and replace the nasal applicator followed by the plastic dust cap.</p><p>Re-prime the pump with 2 sprays when first used after cleaning.</p><p>&nbsp;</p><p><u><strong>a- If you use more MASTASONE than you should</strong></u><br />In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.</p><p>&nbsp;</p><p><u><strong>b- If you forget to use MASTASONE</strong></u><br />If you miss taking your dose on time, do not worry; take a dose if you remember within an hour or so. However, if you do not remember until later, skip the missed dose and go back to your regular dosing schedule. Do not double the dose.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Side effects that may occur with the use of corticosteroid nasal sprays, including MASTASONE, are headache, nose-bleed or blood- tinged mucus, burning or irritation inside the nose, sneezing or sore throat.</p><p>Disturbances of taste and smell have been reported very rarely.</p><p>The following less common side effects have been seen in Clinical Trials: swollen lymph nodes, vision changes, eye tearing, dry eyes, eye inflammation or infection, ear ache, ringing in the ears, stomach pain, constipation, diarrhea, nausea, tongue and tooth disorders, dry mouth, aggravated allergy symptoms, swelling of the body including the face, fever, flu-like symptoms, thirst, cold sore, infections, muscle and/or joint pain, tremor, dizziness, migraine, depression, nightmares causing sleep disturbances, fatigue, loss of voice, bronchitis, shortness of breath, wheezing, acne, skin rashes and high blood pressure.</p><p>In addition to some of the above side effects, the following post-market side effects have been seen: nasal septum perforation.</p><table border="1" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td colspan="5" style="width:614px"><p><strong>SERIOUS</strong><strong> </strong><strong>SIDE</strong><strong> </strong><strong>EFFECTS</strong><strong>, </strong><strong>HOW</strong><strong> </strong><strong>OFTEN</strong><strong> </strong><strong>THEY&nbsp;</strong><strong>HAPPEN</strong><strong> </strong><strong>AND</strong><strong> </strong><strong>WHAT</strong><strong> </strong><strong>TO</strong><strong> </strong><strong>DO</strong><strong> </strong><strong>ABOUT</strong><strong> </strong><strong>THEM</strong></p></td></tr><tr><td colspan="2" rowspan="2"><p dir="RTL"><strong>Symptoms</strong><strong> / </strong><strong>effects</strong></p></td><td colspan="2"><p dir="RTL"><strong>Talk</strong><strong> </strong><strong>with</strong><strong> </strong><strong>your</strong><strong> </strong><strong>doctor</strong><strong> </strong><strong>or</strong><strong> </strong><strong>pharmacist</strong></p></td><td rowspan="2" style="width:110px"><p dir="RTL"><strong>Stop</strong><strong> </strong><strong>taking</strong><strong> </strong><strong>drug</strong><strong> </strong><strong>and</strong><strong> </strong><strong>seek immediate emergency medical attention</strong></p></td></tr><tr><td><p dir="RTL"><strong>Only</strong><strong> </strong><strong>if</strong><strong> </strong><strong>severe</strong></p></td><td><p dir="RTL"><strong>In</strong><strong> </strong><strong>all</strong><strong> </strong><strong>cases</strong></p></td></tr><tr><td><p dir="RTL"><strong>Rare</strong></p></td><td><p>Immediate hypersensitivity: an allergic reaction which may cause sudden onset of wheezing or difficulty in breathing shortly after taking this medication.</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="width:110px"><p>✔</p></td></tr><tr><td><p><strong>Uncommon</strong></p></td><td><p>Chest pain, irregular or fast heartbeat</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="width:110px"><p>✔</p></td></tr></tbody></table><p><strong>IF YOU EXPERIENCE ANY UNDESIRABLE OR TROUBLESOME EFFECTS, INCLUDING ANY THAT ARE NOT LISTED, ADVISE YOUR PHYSICIAN OR PHARMACIST.IF YOU EXPERIENCE ANY UNDESIRABLE OR TROUBLESOME EFFECTS, INCLUDING ANY THAT ARE NOT LISTED, ADVISE YOUR PHYSICIAN OR PHARMACIST.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach of children.</li><li>Stored below 30&deg;C.</li><li>Protect from light.</li><li>Do not freeze.</li><li>Do not use this product after the expiration date on the package.</li><li>Do not use this product after two months from the date of first use.</li></ul><p>When MASTASONE is removed from its cardboard container, prolonged exposure of the product to direct light should be avoided. Brief exposure to light, as with normal use, is acceptable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is mometasone furoate.<br />The other ingredients are benzalkonium chloride, citric acid, glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, purified water and sodium citrate dihydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                MASTASONE comes in a nasal spray device which delivers 140 sprays. Each spray delivers an unscented mist, containing the equivalent of 50 mcg of mometasone furoate.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>c- Marketing Authorization Holder<br />Apotex Inc., Toronto, Ontario, M9L 1T9, Canada</p><p>d- Manufacturer<br />Apotex Inc., Richmond Hill, Ontario, L4C 5H2, Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Apotex Inc. Saudi Arabia
Last revised on 06/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي مستازون إلى فئة الكورتيكوستيرويدات التي تُستخدم لعلاج وتخفيف الالتهابات. لقد وصف لك الطبيب هذا الدواء لعلاج الأعراض المرتبطة بإحدى الحالات التالية:</p><p>&nbsp;</p><p><strong><u>في البالغين والمراهقين والأطفال من 3 سنوات إلى 11 سنة:</u></strong></p><p><br /><strong>التهاب الأنف التحسسي الموسمي:&nbsp;</strong><br />تُسمى هذه الحالة &laquo;حمى القش&raquo; وتحدث بسبب الحساسية تجاه الأعشاب وحبوب اللقاح وما شابه ذلك. وتشمل الأعراض زكام أو احتقان الأنف وسيلان الأنف والحكة والعطاس.</p><p><br /><strong>التهاب الأنف التحسسي الدائم:&nbsp;</strong><br />حالات حساسية مستمرة على مدار العام تحدث بسبب سوس الغبار أو وبر الحيوانات والفطريات. تشمل الأعراض زكام أو احتقان الأنف وسيلان الأنف والحكة والعطاس.</p><p><br /><u><strong>في البالغين والأطفال في عمر 12 سنة فما فوق:&nbsp;</strong></u></p><p><br /><strong>علاج مساعد للمضادات الحيوية في النوبات الحادة من التهاب الأنف والجيوب الأنفية، حيث توجد علامات أو أعراض العدوى البكتيرية:&nbsp;</strong><br />التهاب الأنف والجيوب الأنفية الحاد عبارة عن التهاب في الجيوب الأنفية قد يكون مصحوبًا بعدوى بكتيرية. يُستخدم مستازون لعلاج الجانب الالتهابي ويُستخدم المضاد الحيوي لعلاج العدوى البكتيرية في الجيوب الأنفية. تشمل الأعراض (على سبيل المثال لا الحصر) زكام/احتقان الأنف، سيلان الأنف، شعور بشيء يسيل في مؤخرة الحلق، حمى، ألم شديد في الوجه/الأسنان (خصوصًا في جانب واحد من الوجه)، تورم في الوجه أو إفرازات غليظة من الأنف صفراء أو خضراء اللون.</p><p>&nbsp;</p><p><strong>التهاب الأنف والجيوب الأنفية غير المعقد البسيط إلى المتوسط حيث لا توجد علامات أو أعراض عدوى بكتيرية:&nbsp;</strong><br />يُستخدم مستازون لعلاج الأعراض المرتبطة بالالتهاب وانسداد الجيوب الموجودة خلف الأنف. تشمل الأعراض زكام/احتقان الأنف، سيلان الأنف، شعور بشيء يسيل في مؤخرة الحلق، وضغط أو ألم في الوجه. في حالة تفاقم الأعراض أو حدوث حمى، أو ألم شديد مستمر في الوجه/ الأسنان (خصوصًا في جانب واحد من الوجه)، أو تورم في الوجه أو إفرازات غليظة من الأنف صفراء أو خضراء اللون، يجب استشارة الطبيب على الفور.</p><p>&nbsp;</p><p><u><strong>في البالغين في عمر 18 سنة فما فوق:</strong></u></p><p><br /><strong>البوليبات الأنفية (نوع من التهابات الأنف):&nbsp;</strong><br />نتوءات صغيرة على بطانة الأنف تؤثر عادةً على كلا فتحتي الأنف. يكون العرض الأساسي هو شعور بانسداد الأنف قد يؤثر في التنفس عبر الأنف. قد تشمل الأعراض الأخرى سيلان الأنف، شعور بشيء يسيل في مؤخرة الحلق، وفقدان التذوق والشم.</p><p>&nbsp;</p><p><u><strong>كيفية عمل الدواء:</strong></u><br />عند بخ رذاذ هذا الدواء داخل الأنف؛ يساعد على تقليل أعراض الحالات المذكورة أعلاه.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- موانع استخدام بخاخ مستازون:</strong></u></p><ul><li>إذا كنت تعاني من الحساسية تجاه مادة مستازون أو أيٍ من مكوناته الأخرى.</li><li>إذا كنت تعاني من عدوى بكتيرية في الأنف (أي خروج إفرازات صفراء أو خضراء اللون من الأنف) لا تستجيب للعلاج.</li><li>إذا كنت خضعت لعملية جراحية أوتعرضت لجرح في الأنف مؤخرًا. في هذه الحالة؛ قد يطلب منك الطبيب الانتظار حتى تشفى قبل استخدام مستازون.</li><li>إذا شخَّص الطبيب حالتك بمرض السل وأنها لا تستجيب للعلاج.*</li><li>إذا كنت تعاني من عدوى فطرية أو بكتيرية أو فيروسية شاملة.*</li><li>إذا كنت تعاني من عدوى الهربس البسيط في العين ولا تستجيب للعلاج. *</li></ul><p>*انظر قسم الاحتياطات عند استعمال مستازون للحصول على معلومات إضافية.</p><p><u><strong>ب- الاحتياطات عند استعمال مستازون</strong></u><br />لا تستخدم بخاخ مستازون في العينين أو الفم. هذا الدواء مخصص للاستخدام في الأنف فقط.</p><p>قبل استخدام مستازون؛ ينبغي استشارة الطبيب أو الصيدلي في حالة الحمل أو الرضاعة الطبيعية. ينبغي الامتناع عن الرضاعة الطبيعية أثناء العلاج ببخاخ مستازون.</p><p>ينبغي إخبار الطبيب إذا كنت تعاني من أيٍ من الحالات التالية قبل البدء في استخدام بخاخ مستازون أو في حالة الإصابة بها أثناء العلاج. قد يلزم الطبيب خفض الجرعة التي تأخذها من هذه الدواء، أو قد تحتاج إلى علاج إضافي للسيطرة على الحالة. بمجرد إخبار الطبيب بحالتك سوف يقرر مدى الحاجة إلى إدخال تغييرات في العلاج. في بعض الحالات قد يكون من الضروري إيقاف العلاج.</p><ul><li>قروح في الأنف</li><li>السل (سواء في حالة نشطة أو سابقة)</li><li>عدوى (فطرية أو بكتيرية أو فيروسية)</li><li>عدوى الهربس البسيط في العين</li></ul><p>(انظر قسم <u><strong>موانع استخدام بخاخ مستازون</strong></u> للحصول على معلومات إضافية).</p><p>إذا كنت تظن أنك قد أُصبت بعدوى في الأنف بعد بدء العلاج ببخاخ مستازون (تكون الأعراض عادة هي تحول الإفرازات الشفافة من الأنف إلى إفرازات صفراء أو خضراء اللون)، فاتصل بالطبيب.</p><p>إذا وُصف لك مستازون (ولكن ليس مع مضادات حيوية) لعلاج التهاب الأنف والجيوب الأنفية الحاد غير المعقد البسيط إلى المتوسط، فاستشر الطبيب إذا ظهرت عليك علامات أو أعراض للعدوى البكتيرية (مثل الحمى، ألم شديد مستمر في الوجه/ الأسنان (خصوصًا في جانب واحد من الوجه)، تورم في الوجه، وتفاقم الأعراض بعد تحسن أولي) أو إفرازات غليظة من الأنف صفراء أو خضراء اللون.</p><p>احرص على استخدام هذا الدواء وفقًا لتعليمات الطبيب أو الصيدلي تمامًا بتمام. لا تستخدم جرعة زائدة من مستازون عن تلك التي حددها لك الطبيب ظنًا منك أن هذا سيزيد من مفعول الدواء، ولا تستخدم هذا الدواء مرات أكثر من التي حددها لك الطبيب. لا تستخدم مستازون إلا بوصفة طبية من طبيب متخصص. لا تشارك هذا الدواء مع أي شخص آخر؛ فقد يضر هذا الدواء الآخرين حتى لو كانوا يعانون من أعراض مثل التي تعاني منها. لا تستخدم هذا الدواء لعلاج اضطرابات صحية أخرى.</p><p>&nbsp;</p><p><u><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية</strong></u><br />لتجنب إمكانية تفاعل الأدوية، احرص على إخبار الطبيب أو الصيدلي عن أي أدوية أخرى تستخدمها، وخصوصًا الأدوية من فئة الكورتيكوستيرويدات، سواء التي تؤخذ عن طريق الفم أو عن طريق الحقن. قد يتطلب الأمر تعديل جرعات بعض الأدوية أثناء العلاج بمستازون.</p><p>الأدوية التي يمكن أن تتفاعل مع مستازون تشمل:</p><ul><li dir="rtl">كيتوكينازول</li></ul><p>&nbsp;</p><p><u><strong>فحص تعاطي العقاقير الخاص بالأحداث الرياضية&nbsp;</strong></u></p><p>هذا الدواء عبارة عن كورتيكوستيرويد للاستخدام عن طريق الأنف. وعلى الرغم من أنه لا يمكن قياسه في الدم؛ يمكن اكتشاف الكورتيكوستيرويدات في البول عن طريق فحص تعاطي العقاقير. ولذا قد تطلب الهيئات الرياضية الحصول على تصريح خطي مسبق لاستخدام هذا الدواء.</p><p>&nbsp;</p><p><u><strong>د- استعمال &nbsp;مع الطعام والشراب</strong></u><br />الطعام والشراب ليس لها تأثير.</p><p>&nbsp;</p><p><u><strong>هـ - الحمل والرضاعة</strong></u><br />كما هو الحال مع غيرها من الكورتيكوستيرويدات التي تستخدم عن طريق الانف، مستازون ينبغي أن يستخدم في النساء الحوامل والأمهات المرضعات أو النساء في سن الإنجاب فقط إذا كانت الفائدة المحتملة تفوق المخاطر المحتملة للأم، الجنين، أو الرضع. ينبغي مراعاة الأطفال الذين يولدون من أمهات الذين تلقوا الكورتيزون أثناء الحمل بعناية وملاحظة قصور الغدة الكظرية.</p><p>&nbsp;</p><p><u><strong>و- تأثير &nbsp;على القيادة واستخدام الآلات</strong></u><br />لا يوجد اي تأثير.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدمه في العينين فهو مخصص للاستخدام داخل الأنف فقط.</p><p>&nbsp;</p><p><u><strong>مقدار جرعة مستازون</strong></u><br />في حالة احتقان الأنف الشديد، قد يوصي الطبيب باستخدام مزيل للاحتقان عن طريق الأنف (مضيِّق للأوعية) قبل استخدام مستازون بيومين أو ثلاثة أيام للمساعدة في تنظيف الممرات الأنفية وللمساعدة في إدخال الدواء إلى الجسم.</p><p>&nbsp;</p><p><strong>علاج التهاب الأنف التحسسي الموسمي أو الدائم:</strong></p><ul><li>بالنسبة إلى الأطفال من عمر 3 سنوات إلى 11 سنة؛ الجرعة العادية الموصى بها هي بخة واحدة في كل فتحة أنف مرة واحدة في اليوم. ينبغي مساعدة الأطفال الصغار بواسطة شخص بالغ عند استخدام مستازون.</li><li>بالنسبة إلى البالغين (بما فيهم كبار السن) والأطفال من عمر 12 سنة فما فوق؛ الجرعة العادية الموصى بها هي بختان في كل فتحة أنف مرة واحدة في اليوم. عندما تُصبح الأعراض تحت السيطرة؛ قد يوصي الطبيب بأن تكون الجرعة بخة واحدة في كل فتحة أنف مرة واحدة في اليوم للمحافظة على السيطرة على الأعراض.</li></ul><p>قد يغيِّر الطبيب هذه الجرعة حسب استجابتك للدواء مستازون.</p><p>في بعض المرضى؛ قد يحقق مستازون شفاء الأعراض خلال 12 ساعة، بينما قد يستغرق ذلك 48 ساعة على الأقل في مرضى آخرين. ويتوقف المفعول الكامل على الاستخدام المنتظم والمستمر (بخلاف أدوية أخرى تُستخدم عند الضرورة فقط). للحصول على الفائدة الكاملة للعلاج، استمر في استخدام العلاج بصفة منتظمة.</p><p>&nbsp;</p><p><strong>العلاج المساعد للمضادات الحيوية في النوبات الحادة من التهاب الأنف والجيوب الأنفية:</strong><br />بالنسبة إلى البالغين (بما فيهم كبار السن) والأطفال من عمر 12 سنة فما فوق؛ الجرعة العادية الموصى بها هي بختان في كل فتحة أنف مرتين في اليوم. في حالة الحاجة إلى مزيد من السيطرة على الأعراض؛ قد يوصي الطبيب بزيادة الجرعة إلى أربعة بخات في كل فتحة أنف مرتين في اليوم.</p><p>قد يغيِّر الطبيب هذه الجرعة حسب استجابتك للدواء مستازون.</p><p>&nbsp;</p><p><strong>علاج التهاب الأنف والجيوب الأنفية غير المعقد البسيط إلى المتوسط:</strong><br />بالنسبة إلى البالغين (بما فيهم كبار السن) والأطفال من عمر 12 سنة فما فوق؛ الجرعة العادية الموصى بها هي بختان في كل فتحة أنف مرتين في اليوم.</p><p>يجب الاتصال بالطبيب إذا تفاقمت الأعراض أثناء العلاج (انظر القسم &laquo;الاحتياطات عند استعمال مستازون&raquo;).</p><p>&nbsp;</p><p><strong>علاج البوليبات الأنفية:</strong><br />بالنسبة إلى البالغين من عمر 18 سنة فما فوق (بما فيهم كبار السن)؛ الجرعة العادية الموصى بها هي بختان في كل فتحة أنف مرتين في اليوم. بمجرد السيطرة على الأعراض؛ يمكن للطبيب أن يقلل الجرعة إلى بختين في كل فتحة أنف مرة واحدة يوميًا.</p><p>&nbsp;</p><p><u><strong>كيفية استخدام الدواء مستازون</strong></u><br />اقرأ التعليمات بأكلمها بعناية واستخدم البخاخ حسب التعليمات فقط. رُجّ البخاخ جيدًا قبل كل استخدام.</p><ol><li>قم بإزالة الغطاء البلاستيكي الواقي من الأتربة.&nbsp;<img alt="" width="46" height="46" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAgEASABIAAD/4gxYSUNDX1BST0ZJTEUAAQEAAAxITGlubwIQAABtbnRyUkdCIFhZWiAHzgACAAkABgAxAABhY3NwTVNGVAAAAABJRUMgc1JHQgAAAAAAAAAAAAAAAAAA9tYAAQAAAADTLUhQICAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABFjcHJ0AAABUAAAADNkZXNjAAABhAAAAGx3dHB0AAAB8AAAABRia3B0AAACBAAAABRyWFlaAAACGAAAABRnWFlaAAACLAAAABRiWFlaAAACQAAAABRkbW5kAAACVAAAAHBkbWRkAAACxAAAAIh2dWVkAAADTAAAAIZ2aWV3AAAD1AAAACRsdW1pAAAD+AAAABRtZWFzAAAEDAAAACR0ZWNoAAAEMAAAAAxyVFJDAAAEPAAACAxnVFJDAAAEPAAACAxiVFJDAAAEPAAACAx0ZXh0AAAAAENvcHlyaWdodCAoYykgMTk5OCBIZXdsZXR0LVBhY2thcmQgQ29tcGFueQAAZGVzYwAAAAAAAAASc1JHQiBJRUM2MTk2Ni0yLjEAAAAAAAAAAAAAABJzUkdCIElFQzYxOTY2LTIuMQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAWFlaIAAAAAAAAPNRAAEAAAABFsxYWVogAAAAAAAAAAAAAAAAAAAAAFhZWiAAAAAAAABvogAAOPUAAAOQWFlaIAAAAAAAAGKZAAC3hQAAGNpYWVogAAAAAAAAJKAAAA+EAAC2z2Rlc2MAAAAAAAAAFklFQyBodHRwOi8vd3d3LmllYy5jaAAAAAAAAAAAAAAAFklFQyBodHRwOi8vd3d3LmllYy5jaAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAABkZXNjAAAAAAAAAC5JRUMgNjE5NjYtMi4xIERlZmF1bHQgUkdCIGNvbG91ciBzcGFjZSAtIHNSR0IAAAAAAAAAAAAAAC5JRUMgNjE5NjYtMi4xIERlZmF1bHQgUkdCIGNvbG91ciBzcGFjZSAtIHNSR0IAAAAAAAAAAAAAAAAAAAAAAAAAAAAAZGVzYwAAAAAAAAAsUmVmZXJlbmNlIFZpZXdpbmcgQ29uZGl0aW9uIGluIElFQzYxOTY2LTIuMQAAAAAAAAAAAAAALFJlZmVyZW5jZSBWaWV3aW5nIENvbmRpdGlvbiBpbiBJRUM2MTk2Ni0yLjEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHZpZXcAAAAAABOk/gAUXy4AEM8UAAPtzAAEEwsAA1yeAAAAAVhZWiAAAAAAAEwJVgBQAAAAVx/nbWVhcwAAAAAAAAABAAAAAAAAAAAAAAAAAAAAAAAAAo8AAAACc2lnIAAAAABDUlQgY3VydgAAAAAAAAQAAAAABQAKAA8AFAAZAB4AIwAoAC0AMgA3ADsAQABFAEoATwBUAFkAXgBjAGgAbQByAHcAfACBAIYAiwCQAJUAmgCfAKQAqQCuALIAtwC8AMEAxgDLANAA1QDbAOAA5QDrAPAA9gD7AQEBBwENARMBGQEfASUBKwEyATgBPgFFAUwBUgFZAWABZwFuAXUBfAGDAYsBkgGaAaEBqQGxAbkBwQHJAdEB2QHhAekB8gH6AgMCDAIUAh0CJgIvAjgCQQJLAlQCXQJnAnECegKEAo4CmAKiAqwCtgLBAssC1QLgAusC9QMAAwsDFgMhAy0DOANDA08DWgNmA3IDfgOKA5YDogOuA7oDxwPTA+AD7AP5BAYEEwQgBC0EOwRIBFUEYwRxBH4EjASaBKgEtgTEBNME4QTwBP4FDQUcBSsFOgVJBVgFZwV3BYYFlgWmBbUFxQXVBeUF9gYGBhYGJwY3BkgGWQZqBnsGjAadBq8GwAbRBuMG9QcHBxkHKwc9B08HYQd0B4YHmQesB78H0gflB/gICwgfCDIIRghaCG4IggiWCKoIvgjSCOcI+wkQCSUJOglPCWQJeQmPCaQJugnPCeUJ+woRCicKPQpUCmoKgQqYCq4KxQrcCvMLCwsiCzkLUQtpC4ALmAuwC8gL4Qv5DBIMKgxDDFwMdQyODKcMwAzZDPMNDQ0mDUANWg10DY4NqQ3DDd4N+A4TDi4OSQ5kDn8Omw62DtIO7g8JDyUPQQ9eD3oPlg+zD88P7BAJECYQQxBhEH4QmxC5ENcQ9RETETERTxFtEYwRqhHJEegSBxImEkUSZBKEEqMSwxLjEwMTIxNDE2MTgxOkE8UT5RQGFCcUSRRqFIsUrRTOFPAVEhU0FVYVeBWbFb0V4BYDFiYWSRZsFo8WshbWFvoXHRdBF2UXiReuF9IX9xgbGEAYZRiKGK8Y1Rj6GSAZRRlrGZEZtxndGgQaKhpRGncanhrFGuwbFBs7G2MbihuyG9ocAhwqHFIcexyjHMwc9R0eHUcdcB2ZHcMd7B4WHkAeah6UHr4e6R8THz4faR+UH78f6iAVIEEgbCCYIMQg8CEcIUghdSGhIc4h+yInIlUigiKvIt0jCiM4I2YjlCPCI/AkHyRNJHwkqyTaJQklOCVoJZclxyX3JicmVyaHJrcm6CcYJ0kneierJ9woDSg/KHEooijUKQYpOClrKZ0p0CoCKjUqaCqbKs8rAis2K2krnSvRLAUsOSxuLKIs1y0MLUEtdi2rLeEuFi5MLoIuty7uLyQvWi+RL8cv/jA1MGwwpDDbMRIxSjGCMbox8jIqMmMymzLUMw0zRjN/M7gz8TQrNGU0njTYNRM1TTWHNcI1/TY3NnI2rjbpNyQ3YDecN9c4FDhQOIw4yDkFOUI5fzm8Ofk6Njp0OrI67zstO2s7qjvoPCc8ZTykPOM9Ij1hPaE94D4gPmA+oD7gPyE/YT+iP+JAI0BkQKZA50EpQWpBrEHuQjBCckK1QvdDOkN9Q8BEA0RHRIpEzkUSRVVFmkXeRiJGZ0arRvBHNUd7R8BIBUhLSJFI10kdSWNJqUnwSjdKfUrESwxLU0uaS+JMKkxyTLpNAk1KTZNN3E4lTm5Ot08AT0lPk0/dUCdQcVC7UQZRUFGbUeZSMVJ8UsdTE1NfU6pT9lRCVI9U21UoVXVVwlYPVlxWqVb3V0RXklfgWC9YfVjLWRpZaVm4WgdaVlqmWvVbRVuVW+VcNVyGXNZdJ114XcleGl5sXr1fD19hX7NgBWBXYKpg/GFPYaJh9WJJYpxi8GNDY5dj62RAZJRk6WU9ZZJl52Y9ZpJm6Gc9Z5Nn6Wg/aJZo7GlDaZpp8WpIap9q92tPa6dr/2xXbK9tCG1gbbluEm5rbsRvHm94b9FwK3CGcOBxOnGVcfByS3KmcwFzXXO4dBR0cHTMdSh1hXXhdj52m3b4d1Z3s3gReG54zHkqeYl553pGeqV7BHtje8J8IXyBfOF9QX2hfgF+Yn7CfyN/hH/lgEeAqIEKgWuBzYIwgpKC9INXg7qEHYSAhOOFR4Wrhg6GcobXhzuHn4gEiGmIzokziZmJ/opkisqLMIuWi/yMY4zKjTGNmI3/jmaOzo82j56QBpBukNaRP5GokhGSepLjk02TtpQglIqU9JVflcmWNJaflwqXdZfgmEyYuJkkmZCZ/JpomtWbQpuvnByciZz3nWSd0p5Anq6fHZ+Ln/qgaaDYoUehtqImopajBqN2o+akVqTHpTilqaYapoum/adup+CoUqjEqTepqaocqo+rAqt1q+msXKzQrUStuK4trqGvFq+LsACwdbDqsWCx1rJLssKzOLOutCW0nLUTtYq2AbZ5tvC3aLfguFm40blKucK6O7q1uy67p7whvJu9Fb2Pvgq+hL7/v3q/9cBwwOzBZ8Hjwl/C28NYw9TEUcTOxUvFyMZGxsPHQce/yD3IvMk6ybnKOMq3yzbLtsw1zLXNNc21zjbOts83z7jQOdC60TzRvtI/0sHTRNPG1EnUy9VO1dHWVdbY11zX4Nhk2OjZbNnx2nba+9uA3AXcit0Q3ZbeHN6i3ynfr+A24L3hROHM4lPi2+Nj4+vkc+T85YTmDeaW5x/nqegy6LzpRunQ6lvq5etw6/vshu0R7ZzuKO6070DvzPBY8OXxcvH/8ozzGfOn9DT0wvVQ9d72bfb794r4Gfio+Tj5x/pX+uf7d/wH/Jj9Kf26/kv+3P9t////7gAOQWRvYmUAZAAAAAAB/9sAQwAMCAgICAgMCAgMEAsLCwwPDg0NDhQSDg4TExIXFBIUFBobFxQUGx4eJxsUJCcnJyckMjU1NTI7Ozs7Ozs7Ozs7/9sAQwENCgoMCgwODAwOEQ4ODA0RFBQPDxEUEBEYERAUFBMUFRUUExQVFRUVFRUVGhoaGhoaHh4eHh4jIyMjJycnLCws/9sAQwINCgoMCgwODAwOEQ4ODA0RFBQPDxEUEBEYERAUFBMUFRUUExQVFRUVFRUVGhoaGhoaHh4eHh4jIyMjJycnLCws/8AAEQgALgAuAwAiAAERAQIRAv/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAAABEQIRAD8A7PTNIXUrZ7y4vL4SPdXYIjup40ASeVFAVXAAAUCrf/CNW3/P7qP/AIGXP/xdP8PlhpTFBuYXV/gE4BP2ibAzzWBoGo+J5/FF7b3ckcsClhLBkiOJUbaDEduSeec9aANifw/BEE23moEvIqDN5c8Z6n7/AKCnReHbeSNXN5qGSOcXlz/8XWhf+asKyw7S8cilQ+dpLfIAcf71Ps1ZbaPeQWI3HHA+Y7sd+maAM7/hGrb/AJ/dR/8AAy5/+LrI1/SvsPkfZ7/UF8zzN3+mXB6bMdX9666uf8V/8uv/AG1/9koAu+Hf+QZ/2933/pTNVbS7Mw65e3GP9Z5n6uDVnw7/AMgz/t7vv/SmatBYo1cuowzdTQBVv5pvMitreEyucTH5lUBY2U9yOpIp1hcSyB7eeIwywhcjcrghs7SCCfTpVXUp7iG+ie1V3YQusgSIz7QxUqfvpjJU96fpMlxNNdTXSsjs0aoHjMJKKvBwXf8AiYjr2oA0q5/xX/y6/wDbX/2Sugrn/Ff/AC6/9tf/AGSgC74d/wCQZ/2933/pTNWnXD2vjvTdFE2mXFvO8kF5eBmjCFDunlcYy4PRvSpv+Fn6P/z63P5R/wDxygDq0/4/Zf8ArjF/OSnj/Xt/1zX+bVxp+JOj+a0y290pZVUjERGFJI/j/wBqnL8S9HVi5t7piQB0iA4z/t+9AHaVz/iv/l1/7a/+yVm/8LP0f/n1ufyj/wDjlZeuePdM1DyPKt518vzM7tg+9t9GPpQB/9k=" /></li><li>عند استخدام البخاخ لأول مرة؛ قم بعمل اختبار للمضخة عن طريق الضغط لأسفل على الطرفين الجانبيين للمبسم الأبيض وذلك باستخدام الإصبعين السبابة والوسطى أثناء&nbsp;إسناد الجزء السفلي من العبوة بالإصبع الإبهام. اضغط&nbsp; لأسفل ثم حرر المضخة 10 مرات أو حتى يظهر رذاذ دقيق. بهذا تصبح المضخة جاهزة للاستخدام. يمكن تخزين المضخة بدون استخدام لمدة أسبوعين دون إجراء اختبار التشغيل مرة أخرى. إذا تُركت المضخة دون استخدام لأكثر من أسبوعين، فقم بعمل اختبار التشغيل مرتين حتى يظهر رذاذ دقيق.&nbsp;<img alt="" width="46" height="46" src="data:image/jpeg;base64,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" /></li><li>استنثر أنفك برفق لتنظيف فتحتي الأنف. أغلق إحدى فتحتي الأنف بأصبعك. أمِل رأسك للأمام قليلاً وأمسك بالعبوة في وضع مستقيم ثم أدخل مبسم الأنف داخل فتحة الأنف المفتوحة.&nbsp;<img alt="" width="47" height="46" src="data:image/jpeg;base64,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" /></li><li>في كل بخة؛ اضغط مرة واحدة بقوة لأسفل على الطرفين الجانبيين للمبسم الأبيض وذلك باستخدام الإصبعين السبابة والوسطى أثناء إسناد الجزء السفلي من العبوة بالإصبع الإبهام. قم بإجراء البخة أثناء التنفس برفق للداخل عبر فتحة الأنف مع إغلاف الفم.&nbsp;<img alt="" width="46" height="45" src="data:image/jpeg;base64,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" /></li><li>بعد ذلك ازفر من خلال الفم.&nbsp;<img alt="" width="46" height="46" src="data:image/jpeg;base64,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" /></li><li>كرر نفس الإجراء في فتحة الأنف الأخرى.</li><li>أعِد الغطاء الواقي من الأتربة إلى مكانه على المضخة بعد كل استخدام.</li></ol><p>تكفي الكمية الصحيحة من الدواء الموجود في كل عبوة حتى 140 بخة على الرغم من أن العبوة قد لا تكون فارغة تمامًا. يجب تسجيل عدد البخات المستخدمة من كل عبوة من عبوات مستازون، والتخلص من العبوة بعد استخدام 140 بخة (مدة 5 أسابيع تقريبًا من الاستخدام حسب الجرعة الموصوفة).</p><p><strong>التنظيف:</strong> لتنظيف مبسم الأنف، قم بإزالة الغطاء البلاستيكي الواقي من الأتربة واسحب مبسم الأنف الأبيض لأعلى برفق حتى يتحرر عن العبوة. اغسل المبسم والغطاء الواقي من الأتربة تحت صنبور ماء بارد. <strong>لا تحاول تسليك مبسم الأنف عن طريق إدخال دبوس أو أي أداة حادة أخرى لأن هذا سيؤدي إلى إتلاف المبسم وعدم حصولك على الجرعة الصحيحة من الدواء.</strong> قم بتجفيف مبسم الأنف وتركيبه في مكانه ثم الغطاء البلاستيكي الواقي من الأتربة.</p><p>قم بعمل اختبار تشغيل المضخة عن طريق بختين عند استخدام المضخة لأول مرة بعد تنظيفها.</p><p>&nbsp;</p><p><u><strong>أ- في حالة تناول جرعة زائدة من مستازون</strong></u><br />في حالة تناول جرعة زائدة من الدواء، اتصل على الفور بالطبيب أو قسم الطوارئ بالمستشفى أو بمركز مكافحة السموم الإقليمي لديك، حتى لو لم تظهر أعراض.</p><p>&nbsp;</p><p><u><strong>ب- في حالة نسيان جرعة مستازون</strong></u><br />في حالة نسيان جرعة في وقتها، لا تقلق، وخذ الجرعة إذا تذكرتها خلال ساعة أو قريبًا منها. ولكن إذا لم تتذكر إلا بعد وقت أطول من ذلك؛ فاترك الجرعة المنسية وتابع جدول الجرعات المنتظمة الذي تسير عليه. لا تستخدم جرعة مزدوجة.&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الآثار الجانبية التي قد تحدث مع استخدام بخاخ أنف كورتيكوستيرويد، بما في ذلك مستازون تشمل: صداع، نزيف من الأنف أو مخاط مشوب بدم، حرقان أو تهيج داخل الأنف، عطاس أو التهاب الحلق.</p><p>تم الإبلاغ عن حدوث اضطرابات في التذوق والشم في حالات نادرة جدًا.</p><p>لوحظ حدوث الآثار الجانبية التالية بمعدل أقل شيوعًا في التجارب السريرية: تضخم الغدد الليمفاوية، وتغيرات في الإبصار، تدمُّع العين، جفاف العين، التهاب أو عدوى في العين، ألم في الأذن، طنين في الأذنين، ألم في المعدة، إمساك، إسهال، غثيان، اضطرابات اللسان والأسنان، جفاف الفم، تفاقم أعراض الحساسية، تورم في الجسم بما في ذلك الوجه والحمى وأعراض تشبه الانفلونزا، عطش، قرحة باردة، التهابات، ألم في العضلات و/ أو المفاصل، رعشة، دوخة، صداع نصفي، اكتئاب، أحلام مزعجة تسبب اضطرابات في النوم، تعب، فقدان الصوت، التهاب الشعب الهوائية، ضيق في التنفس، صفير في التنفس، حب شباب، طفح جلدي وارتفاع ضغط الدم.</p><p>إضافةً إلى بعض الآثار الجانبية المذكورة أعلاه، تم الإبلاغ عن الآثار الجانبية التالية في مرحلة ما بعد التسويق: انثقاب الحاجز الأنفي.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td colspan="2" rowspan="2"><p dir="RTL"><strong>العرض/الآثر</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن تناول الدواء واتصل بالطبيب أو الصيدلي</strong></p></td></tr><tr><td><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td rowspan="1"><p dir="RTL"><strong>نادرة</strong></p></td><td><p dir="RTL">فرط حساسية فوري:<br />رد فعل تحسسي قد يسبب حدوث صفير مفاجئ أو صعوبة في النتفس عقب استخدام الدواء</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td></tr><tr><td rowspan="1"><p dir="RTL"><strong>غير شائعة</strong></p></td><td><p dir="RTL">ألم في الصدر، سرعة نبض القلب بشكل غير معتاد</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">&nbsp;</p></td><td><p>✔</p></td></tr></tbody></table><p><strong>إذا تعرضت لأي آثار جانبية ضارة أو مزعجة بما في ذلك أي آثار غير المذكورة أعلاه؛ فأخبر الطبيب أو الصيدلي بذلك.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl">احفظ الأدوية بعيدًا عن متناول الأطفال.</li><li dir="rtl">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</li><li dir="rtl">احفظه من الضوء.</li><li dir="rtl">يجب عدم تجميد الدواء.</li><li dir="rtl">لا تستخدم هذا الدواء بعد تاريخ إنتهاء الصلاحية المكتوب على العبوة.</li><li dir="rtl">لا تستخدم هذا الدواء بعد شهرين من تاريخ أول إستخدام.<br />&nbsp;</li></ul><p>عند إخراج بخاخ مستازون من العبوة الكرتونية؛ يجب تجنب تعريض البخاخ للضوء المباشر لفترات طويلة. يُسمح بالتعرض المحدود للضوء في حالة الاستخدام العادي.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي موميتازون فيوروات<br />باقي المواد هي كلوريد بنزالكونيوم، حمض ستريك، جلسرين، سيلولوز دقيق البللورات، صوديوم كاربوكسي ميثيل سيلولوز، بولي سوربيت 80، ماء نقي وسيترات الصوديوم ثنائي الهيدرات.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يأتي مستازون في شكل جهاز بخاخ للأنف يحتوي على 140 بخة. يخرج مع كل بخة رذاذ عديم الرائحة يحتوي على ما يعادل 50 ميكروجرام من مادة موميتازون فيوروات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 06/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MASTASONE
Mometasone Furoate Aqueous Nasal Spray 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dosage Forms

MASTASONE is formulated as an aqueous nasal suspension for nasal administration via a metered-dose manual pump spray delivering 140 doses of 50 mcg mometasone furoate.

Composition

Each actuation delivers approximately 100 mg of mometasone furoate suspension, containing 50 mcg of mometasone furoate.

The nonmedicinal ingredients include benzalkonium chloride, citric acid, glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, purified water and sodium citrate dihydrate.

Packaging

MASTASONE is supplied in a single pack (1 bottle).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MASTASONE comes in a nasal spray device which delivers 140 sprays. Each spray delivers an unscented mist, containing the equivalent of 50 mcg of mometasone furoate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MASTASONE (mometasone furoate aqueous nasal spray) is indicated for:</p><ul><li>use in adults, adolescents, and children between the ages of 3 and 11 years to treat the symptoms of seasonal or perennial allergic rhinitis.</li><li>use in adults and children 12 years of age and older as adjunctive treatment to antibiotics in acute episodes of rhinosinusitis, where signs or symptoms of bacterial infection are present.</li><li>use in adults and children 12 years of age and older in the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis where signs or symptoms of bacterial infection are not present.</li><li>the treatment of nasal polyps in adult patients 18 years of age or older.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Dosing Considerations</u></strong></p><p>The therapeutic effects of corticosteroids, unlike those of decongestants, are not immediate. Since the effect of mometasone furoate aqueous nasal spray depends on its regular use, patients should be instructed to take the nasal inhalation at regular intervals and not, as with other nasal sprays, as they feel necessary.</p><p>In the presence of excessive nasal mucous secretion or edema of the nasal mucosa, the drug may fail to reach the site of action. In such cases, it is advisable to use a nasal vasoconstrictor for 2 to 3 days prior to starting treatment with mometasone furoate aqueous nasal spray.</p><p>&nbsp;</p><p><strong><u>Recommended Dose and Dosage Adjustment</u></strong></p><p><em><strong>Treatment of seasonal or perennial allergic rhinitis:</strong></em></p><p><u>Adults (including geriatric patients) and children 12 years of age and older</u>: The usual recommended dose is two sprays (50 mcg/spray) in each nostril once daily (total daily dose of 200 mcg). Once symptoms are controlled, dose reduction to one spray in each nostril once daily (total daily dose 100 mcg) may be effective for maintenance.</p><p>If symptoms are inadequately controlled, the dose may be increased to four sprays in each nostril once daily (total daily dose of 400 mcg). Dose reduction is recommended following control of symptoms.</p><p>Clinically significant onset of action occurs as early as 12 hours after the first dose.</p><p>&nbsp;</p><p><u>Children between the ages of 3 and 11 years</u>: The usual recommended dose is one spray (50 mcg/spray) in each nostril once daily (total daily dose of 100 mcg).</p><p>Administration to young children should be aided by an adult.</p><p>&nbsp;</p><p><em><strong>Adjunctive treatment to antibiotics in acute episodes of rhinosinusitis:</strong></em></p><p>Mometasone furoate aqueous nasal spray should not be used in the presence of untreated localized infection involving the nasal mucosa.</p><p><u>Adults (including geriatric patients) and children 12 years of age and older</u>: The usual recommended dose is two sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg).</p><p>If symptoms are inadequately controlled, the dose may be increased to four sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 800 mcg).</p><p>&nbsp;</p><p><em><strong>Treatment of mild to moderate uncomplicated acute rhinosinusitis:</strong></em></p><p>Patients should not use mometasone furoate aqueous nasal spray without an antibiotic if bacterial infection of the sinuses is present or suspected.</p><p>&nbsp;</p><p><u>Adults (including geriatric patients) and children 12 years of age and older</u>: The usual recommended dose is two sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg).</p><p>If signs or symptoms of severe bacterial infection are observed during treatment (such as fever, persistent severe unilateral facial/tooth pain, orbital or peri-orbital facial swelling, or worsening of symptoms after an initial improvement), the patient should be advised to consult their physician immediately, at which time the physician may advise the patient to stop using mometasone furoate aqueous nasal spray.</p><p>Safety and efficacy of mometasone furoate monohydrate aqueous nasal spray in the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis beyond 15 days have not been evaluated.</p><p>&nbsp;</p><p><em><strong>Treatment of Nasal Polyps:</strong></em></p><p><u>Adults (including geriatric patients) and adolescents 18 years of age and older</u>: The usual recommended dose is two sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg).</p><p>Once the symptoms are controlled, dose reduction to two sprays (50 mcg/spray) in each nostril once daily (total daily dose 200 mcg) may be effective for continued treatment.</p><p>Efficacy and safety studies of mometasone furoate monohydrate aqueous nasal spray for the treatment of nasal polyps were four months in duration.</p><p>&nbsp;</p><p><strong><u>Administration</u></strong></p><p>Each actuation delivers approximately 100 mg of mometasone furoate suspension, containing 50 mcg mometasone furoate. Prior to administration, mometasone furoate aqueous nasal spray nasal pump should be primed by actuating the pump 10 times (until a uniform spray is observed). If the spray pump has not been used for 14 days or longer, it should be reprimed with 2 actuations, until a uniform spray is observed, before next use.</p><p>SHAKE CONTAINER WELL BEFORE EACH USE.</p><p>Patients should be instructed on the correct method of use, which is to blow the nose, then insert the nozzle carefully into the nostril, compress the opposite nostril and actuate the spray while inspiring through the nose, with the mouth closed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

MASTASONE should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, or in untreated fungal, bacterial, systemic viral infections or ocular herpes simplex.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>General</u></strong></p><p>During transfer from systemic corticosteroid to mometasone furoate aqueous nasal spray, some patients may experience symptoms of withdrawal from systemically active corticosteroids (e.g., joint and/or muscular pain, lassitude, and depression initially) despite relief from nasal symptoms and will require encouragement to continue mometasone furoate aqueous nasal spray therapy. Such transfer may also unmask pre-existing allergic conditions such as allergic conjunctivitis and eczema, previously suppressed by systemic corticosteroid therapy.</p><p>&nbsp;</p><p><em><strong>Acute Rhinosinusitis:</strong></em></p><p>Patients should not use mometasone furoate aqueous nasal spray without an antibiotic if bacterial infection of the sinuses is present or suspected.</p><p>Mometasone furoate aqueous nasal spray is not indicated to treat the symptoms of the common cold. To distinguish mild to moderate acute rhinosinusitis from the common cold, patients should have symptoms of acute rhinosinusitis persisting or increasing for at least seven days before starting mometasone furoate aqueous nasal spray treatment.</p><p>If signs or symptoms of severe bacterial infection are observed during treatment (such as fever, persistent severe unilateral facial/tooth pain, orbital or peri-orbital facial swelling, or worsening of symptoms after an initial improvement), the patient should be advised to consult their physician immediately at which time the physician may advise the patient to stop using mometasone furoate aqueous nasal spray.</p><p>Safety and efficacy of mometasone furoate monohydrate aqueous nasal spray in the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis beyond 15 days has not been evaluated.</p><p>&nbsp;</p><p><strong><u>Ear/Nose/Throat</u></strong></p><p>Mometasone furoate aqueous nasal spray should not be used in the presence of untreated localized infection involving the nasal mucosa.</p><p>Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred.</p><p>Following 12 months of treatment with mometasone furoate monohydrate aqueous nasal spray, there was no evidence of atrophy of the nasal mucosa; also, mometasone furoate tended to reverse the nasal mucosa closer to a normal histologic phenotype. As with any long-term treatment, patients using mometasone furoate aqueous nasal spray over several months or longer should be examined periodically for possible changes in the nasal mucosa. If localized fungal infection of the nose or pharynx develops, discontinuance of mometasone furoate aqueous nasal spray therapy or appropriate treatment may be required. Persistence of nasopharyngeal irritation may be an indication for discontinuing mometasone furoate aqueous nasal spray.</p><p>Following the use of intranasal aerosolized corticosteroids, instances of nasal septum perforation have been reported very rarely.</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong></p><p>There is no evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression following prolonged (12 months) treatment with mometasone furoate monohydrate aqueous nasal spray. However, patients who are transferred from long-term administration of systemically active corticosteroids to mometasone furoate aqueous nasal spray require careful attention. Systemic corticosteroid withdrawal in such patients may result in adrenal insufficiency for a number of months until recovery of HPA axis function. If these patients exhibit signs and symptoms of adrenal insufficiency, systemic corticosteroid administration should be resumed and other modes of therapy and appropriate measures instituted.</p><p>&nbsp;</p><p><strong><u>Immune</u></strong></p><p>Patients receiving corticosteroids who are potentially immunosuppressed should be warned of the risk of exposure to certain infections (e.g., chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs.</p><p>&nbsp;</p><p><strong><u>Ophthalmologic</u></strong></p><p>Following the use of intranasal aerosolized corticosteroids, instances of increased intraocular pressure have been reported very rarely.</p><p>&nbsp;</p><p><strong><u>Special Populations</u></strong></p><p><em><strong>Pediatrics</strong></em></p><p>Mometasone furoate monohydrate aqueous nasal spray permitted normal growth in a placebo-controlled clinical trial in which pediatric patients were administered mometasone furoate monohydrate aqueous nasal spray 100 mcg daily for one year.</p><p>Safety and efficacy of mometasone furoate monohydrate aqueous nasal spray as adjunctive treatment to antibiotics in acute episodes of rhinosinusitis in children less than 12 years of age have not been studied.</p><p>Safety and efficacy of mometasone furoate monohydrate aqueous nasal spray for the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis in children less than 12 years of age have not been studied.</p><p>Safety and efficacy of mometasone furoate monohydrate aqueous nasal spray for the treatment of nasal polyps in children and adolescents less than 18 years of age have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Drug-Drug Interactions</u></strong></p><p>Mometasone furoate monohydrate aqueous nasal spray has been administered concomitantly with loratadine with no apparent effect on plasma concentrations of loratadine or its major metabolite. In these studies, mometasone furoate plasma concentrations were not detectable using an assay with a LLOQ of 50 pg/mL. The combination therapy was well tolerated.</p><p>&nbsp;</p><p><u>Inhibitors of Cytochrome P450 3A4: </u>Studies have shown that mometasone furoate is primarily and extensively metabolized in the liver of all species investigated and undergoes extensive metabolism to multiple metabolites. In vitro studies have confirmed the primary role of cytochrome CYP 3A4 in the metabolism of this compound. Coadministration with ketoconazole, a potent CYP 3A4 inhibitor, may increase the plasma concentrations of mometasone furoate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy Category C</strong></p><p>There are no adequate or well-controlled studies in pregnant or nursing women.</p><p>As with other nasal corticosteroid preparations, mometasone furoate aqueous nasal spray should be used in pregnant women, nursing mothers or women of childbearing age only if the potential benefit justifies the potential risk to the mother, fetus, or infant. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No or negligible influence.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rarely, immediate hypersensitivity reactions (e.g., bronchospasm, dyspnea) may occur after intranasal administration of mometasone furoate monohydrate. Very rarely, anaphylaxis and angioedema have been reported.</p><p>Disturbances of taste and smell have been reported very rarely.</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p><em>Because</em><em> clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates</em>.</p><p>&nbsp;</p><p><em><strong>Allergic Rhinitis:</strong></em></p><p><u>Adults</u><u> and adolescents &ge;12 years of age: </u>Table 1 demonstrates the incidence of treatment related Undesirable effects associated with mometasone furoate monohydrate aqueous nasal spray based upon the pooled data from clinical trials.</p><p>&nbsp;</p><p><strong>Table 1: Treatment related Undesirable effects occurring at an incidence of &ge;1% and more commonly than placebo</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Undesirable</strong><strong> </strong><strong>effects</strong></p></td><td style="vertical-align:top"><p><strong>Mometasone</strong><strong> </strong><strong>Furoate Monohydrate Aqueous Nasal Spray*</strong></p><p><strong>n=3210</strong><strong> </strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong></p><p><strong>n=1671 </strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>265 (8)</p></td><td style="vertical-align:top"><p>101 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>267 (8)</p></td><td style="vertical-align:top"><p>89 (5)</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>124 (4)</p></td><td style="vertical-align:top"><p>58 (3)</p></td></tr></tbody></table><p>* 50 mcg to 800 mcg of mometasone furoate daily</p><p>&nbsp;</p><p>Treatment-related local adverse events reported in clinical studies, headache, epistaxis (e.g., frank bleeding, blood-tinged mucus, and blood flecks), pharyngitis, and nasal ulceration are typically observed with use of a corticosteroid nasal spray. In addition, the following adverse events occurred at a frequency equal to or less than placebo, nasal burning (2% vs. 3%) and nasal irritation (2% vs. 2%), respectively.</p><p>Epistaxis was generally self-limiting and mild in severity, and occurred at a higher incidence compared to placebo (5%), but at a comparable or lower incidence compared to the active control nasal corticosteroids studied (up to 15%). The incidence of all other effects was comparable with that of placebo.</p><p><u>Pediatric patients 3 to 11 years of age: </u>In the pediatric population, the incidence of adverse effects, e.g. headache (3%), epistaxis (6%), nasal irritation (2%), and sneezing (2%) was comparable to placebo.</p><p>&nbsp;</p><p><em><strong>Acute Rhinosinusitis as Adjunctive Treatment to Antibiotics:</strong></em></p><p>In adults and adolescent patients receiving mometasone furoate monohydrate aqueous nasal spray as adjunctive treatment for acute episodes of rhinosinusitis, treatment-related adverse events, which occurred at an incidence comparable to placebo, included headache (2%), pharyngitis (1%), nasal burning (1%), and nasal irritation (1%). Epistaxis was mild in severity and also occurred at an incidence comparable to placebo (5% vs. 4%, respectively).</p><p>&nbsp;</p><p><em><strong>Mild to Moderate Uncomplicated Acute Rhinosinusitis:</strong></em></p><p>In patients treated for mild to moderate acute rhinosinusitis, the overall incidence of adverse events was comparable to placebo and similar to that observed for patients with allergic rhinitis.</p><p>&nbsp;</p><p><em><strong>Nasal Polyps:</strong></em></p><p>In patients treated for nasal polyps, the overall incidence of adverse events was comparable to placebo and similar to that observed for patients with allergic rhinitis.</p><p>&nbsp;</p><p><strong><u>Less Common Clinical Trial Adverse Drug Reactions (&lt;1%)</u></strong></p><p>The following additional treatment related Undesirable effects occurred in clinical trials in patients using mometasone furoate monohydrate aqueous nasal spray with an incidence of &lt;1% and occurred at a greater incidence than placebo*:</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders: </em>lymphadenopathy</p><p><em>Cardiac</em><em> disorders: </em>palpitation, tachycardia</p><p><em>Eye</em><em> disorders: </em>lacrimation, conjunctivitis, dry eyes, abnormal vision</p><p><em>Ear</em><em> and labyrinth disorders: </em>earache, tinnitus</p><p><em>Gastrointestinal</em><em> </em><em>disorders:</em><em> </em>abdominal pain, constipation, diarrhea, gastritis, nausea, tongue disorder, tooth disorder</p><p><em>General</em><em> </em><em>disorders</em><em> </em><em>and</em><em> </em><em>administration</em><em> </em><em>site</em><em> </em><em>conditions</em>: dry mouth, allergy aggravated, chest pain, edema, face edema, fever, influenza like symptoms, thirst, taste perversion</p><p><em>Infections</em><em> </em><em>and infestations: </em>cold sore non herpetic, infection, bacterial infection</p><p><em>Investigations:</em><em> </em>hepatic enzymes increased</p><p><em>Musculoskeletal</em><em> </em><em>and connective tissue disorders</em>: arthralgia, myalgia</p><p><em>Nervous</em><em> </em><em>system disorders:</em><em> </em>tremor, vertigo, migraine</p><p><em>Psychiatric</em><em> </em><em>disorders:</em><em> </em>depression, paranoia, somnolence</p><p><em>Respiratory,</em><em> </em><em>thoracic</em><em> </em><em>and mediastinal disorders: </em>dysphonia, bronchitis, dyspnea, laryngitis, nasal septum ulceration, sinusitis, wheezing</p><p><em>Skin and subcutaneous tissue disorders: </em>acne, dermatitis, erythematous rash</p><p><em>Vascular</em><em> disorders: </em>hypertension</p><p>*Events reported by more than 1 patient</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>The following Undesirable effects have been identified during the post-marketing period for mometasone furoate monohydrate aqueous nasal spray: anaphylaxis and angioedema, disturbances in smell and nasal septal perforation. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp;</p><p><strong>-&nbsp; To report any side effect(s):</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p>&nbsp;</p><p>Because the systemic bioavailability is &lt;1% (using a sensitive assay with a lower quantitation limit of 0.25 pg/mL) after administration of mometasone furoate via mometasone furoate monohydrate aqueous nasal spray, overdose is unlikely to require any therapy other than observation, followed by initiation of the appropriate prescribed dosage.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><strong>Pharmacology</strong></em></p><p>Mometasone furoate significantly inhibits the release of leukotrienes from leukocytes of allergic patients. In addition,&nbsp;it is an inhibitor of the production of the Th2 cytokines,&nbsp;IL-4 and IL-5, from human CD4+ T-cells.</p><p>In two clinical studies using nasal antigen challenge, mometasone aqueous nasal spray has shown anti- inflammatory activity in both the early and late phase allergic responses. This has been demonstrated by decreases (versus placebo) in histamine and eosinophil activity and reductions (versus baseline) in eosinophils, neutrophils and epithelial cell adhesion proteins. The clinical significance of these findings is not known.</p><p>In patients with seasonal allergic rhinitis, mometasone furoate monohydrate aqueous nasal spray demonstrated a clinically significant onset of action within 12 hours of the first dose.</p><p>In children, results from plasma samples assayed for mometasone furoate monohydrate aqueous nasal spray from one clinical study (Phase III) and two multiple-dose Phase I studies confirmed the general absence of systemic plasma concentrations following intranasal administration of mometasone furoate monohydrate aqueous nasal spray.</p><p>In patients with acute rhinosinusitis, where signs or symptoms of bacterial infection are present, mometasone furoate monohydrate aqueous nasal spray, as adjunctive treatment to antibiotics, produced a significant decrease in total symptom scores, with regards to nasal symptoms (purulent rhinorrhea, postnasal drip and stuffiness/congestion) and non-nasal symptoms (sinus headache, facial pain/pressure/tenderness and cough).</p><p>In patients with mild-moderate uncomplicated acute rhinosinusitis, where signs or symptoms of bacterial infection are not present, clinical trials demonstrated efficacy of mometasone furoate monohydrate aqueous nasal spray as an effective monotherapy. Furthermore, there was no evidence suggestive of increased rhinosinusitis recurrence or predisposition to bacterial infections after mometasone furoate monohydrate aqueous nasal spray monotherapy cessation.</p><p>&nbsp;</p><p><strong><u>Mechanism of Action</u></strong></p><p>Mometasone furoate is a topical glucocorticosteroid with local anti-inflammatory properties at doses that are minimally systemically active.</p><p>&nbsp;</p><p><strong><u>Pharmacodynamics</u></strong></p><p>In two clinical studies utilizing nasal antigen challenge, mometasone furoate monohydrate aqueous nasal spray has shown anti-inflammatory activity in both the early- and late-phase allergic responses. This has been demonstrated by decreases (vs. placebo) in histamine and eosinophil activity and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these finding is not known.</p><p>Two Phase I studies conducted to assess the systemic exposure and tolerability of mometasone furoate monohydrate aqueous nasal spray in children aged 3 to 12 years showed no clinically relevant systemic exposure to mometasone furoate monohydrate aqueous nasal spray and indicated that mometasone furoate monohydrate aqueous nasal spray was well tolerated. A third Phase I study in children aged 6 to12 years showed normal short-term lower leg growth velocity.</p><p>The results of Phase II and Phase III studies indicated no evidence of HPA- (hypothalamic-pituitary-adrenal) axis suppression following treatment with mometasone furoate monohydrate aqueous nasal spray and demonstrated that mometasone furoate monohydrate aqueous nasal spray can alleviate the allergic symptoms in pediatric patients aged 3 to 12 years with seasonal and perennial allergic rhinitis.</p><p>In cell culture, mometasone furoate was shown to be at least ten times more potent than other steroids, including beclomethasone dipropionate (BDP), betamethasone, hydrocortisone and dexamethasone, at inhibiting the synthesis/release of IL-1, IL-6 and TNFa. Mometasone furoate (IC50 = 0.12 nM) was also at least six times more potent than BDP and betamethasone at inhibiting IL-5 production.</p><p>In a preclinical model, the compound has been shown to reduce the accumulation of eosinophils markedly at the site of an allergic reaction. For example, in allergic mice with IgE-mediated allergy, inhaled mometasone furoate at doses as low as 13 mcg/kg inhibited eosinophil infiltration into bronchoalveolar lavage fluid and the lung bronchi and bronchioles. Additionally, mometasone furoate reduced the number of lymphocytes, and the levels of messenger RNA for the proallergic cytokines IL-4 and IL-5.</p><p>Mometasone furoate is devoid of androgenic, antiandrogenic, estrogenic or antiestrogenic activity but, like other glucocorticosteroids, it exhibits some antiuterotrophic activity and delays vaginal opening in animal models at high oral doses of 56 mg/kg/day and 280 mg/kg/day. In general pharmacodynamic activity studies, mometasone furoate did not show mineralocorticoid activity. MF did not exert prominent effects on the central or autonomic nervous system. No significant effect was seen on blood pressure, heart rate, or ECG recordings. Mometasone furoate did not alter secretion of gastric acid, pepsin or bile. Mometasone furoate increased urine volume and potassium secretion only at very high doses given subcutaneously. No effect was seen on basic respiratory function. These results suggest no particular adverse effect or class of effects associated with administration of mometasone furoate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacokinetics</u></strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Absorption:</em></strong></p><p>Mometasone furoate monohydrate, administered as a nasal spray, has a systemic bioavailability of &lt;1% in plasma, using a sensitive assay with a lower quantitation limit (LLOQ) of 0.25 pg/mL. Mometasone furoate suspension is very poorly absorbed from the gastrointestinal tract, and the small amount that may be swallowed and absorbed undergoes extensive first-pass metabolism prior to excretion in urine and bile.</p><p>&nbsp;</p><p><strong><em>Distribution:</em></strong></p><p>The <em>in vitro </em>protein binding for mometasone furoate was reported to be 98% to 99% in concentration range of 5 to 500 ng/mL.</p><p>&nbsp;</p><p><strong><em>Metabolism:</em></strong></p><p>Studies have shown that any portion of a mometasone furoate dose which is swallowed and absorbed undergoes extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon <em>in vitro </em>incubation, one of the minor metabolites formed is 6&szlig;-hydroxymometasonefuroate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4 (CYP3A4).</p><p>&nbsp;</p><p><strong><em>Elimination:</em></strong></p><p>Following intravenous administration, the effective plasma elimination half-life of mometasone furoate is 5.8 hours. Any absorbed drug is excreted as metabolites mostly via the bile, and to a limited extent, into the urine.</p><p>The intranasal administration of mometasone furoate suspension resulted in either very low / dose-proportional / gender independent or nonquantifiable plasma drug concentrations. Similar results were seen for total radioactivity upon intranasal dosing with radiolabeled drug.</p><p>By comparison with the AUC following IV dosing, the absolute bioavailability of MF following intranasal administration was less than 1% in rats and dogs, and following PO (suspension) administration was 1.4% in rats and 1.7% in mice. In dogs, plasma drug concentrations were generally not quantifiable following PO administration of the MF suspension. The pharmacokinetics of mometasone furoate in the mouse, rat and especially dog, were quite comparable to those obtained in humans.</p><p>Mometasone furoate, administered as an aqueous nasal spray, has a systemic bioavailability of &lt;1% in plasma, using a sensitive assay with a lower quantitation limit (LLOQ) of 0.25 pg/mL. Mometasone furoate suspension is very poorly absorbed from the gastrointestinal tract, and the small amount that may be absorbed undergoes extensive first-pass hepatic metabolism prior to excretion in urine and bile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a series of studies designed to maximize exposure to mometasone furoate, there was no unique or special finding regardless of route of administration or formulation. In single- and multiple-dose toxicology studies and in reproductive toxicity studies, all findings were typical glucocorticoid class effects and obeyed the well-established dose-response and dose-duration relationships for systemic pharmacologic effects of glucocorticoids. Difficult and prolonged parturition observed in Segment I and Segment III reproduction studies may be related to the progestational effect of mometasone furoate. Reductions in maternal weight gain, fetal weight, and offspring viability, and the occurrence of typical malformations and skeletal variations (reduced ossification) were glucocorticoid class effects.</p><p>&nbsp;</p><p>Based on results of multiple mutagenicity studies and of two carcinogenicity studies, one each in mice and rats, mometasone furoate should not pose a genetic hazard or increase the risk of cancer to patients exposed in a clinical setting. In particular, there was no statistically significant dose-response relationship for any tumour type in either the mouse or rat carcinogenicity study. In the study with mice, an apparent increase in mesenchymal tumours of the bladder and seminal vesicles was considered to have no relevance to assessment of human risk because it is a species- and strain- specific finding without a human correlate. An apparent increase in incidence of pancreatic cell hyperplasia in mid- and high-dose groups (1.0 and 2.0 mcg/L, respectively), and islet cell neoplasia in the high-dose group of male rats was attributed to the well- established metabolic effects of prolonged administration of glucocorticoids (increased glucose and/or insulin resistance). Increases in the incidence of tumours of islet cells are induced by other steroids, and reflect a non-genotoxic mechanism in a species with unique endocrinologic sensitivity.</p><p>&nbsp;</p><p><em><strong>Acute Toxicity</strong></em></p><p>Two acute inhalation toxicity studies were conducted in mice (i.e., 4-hr whole-body exposure to micronized, pure, mometasone furoate powder). In the first study, the mean estimated doses were 582 mg/kg (in mice) and 394 mg/kg (for rats), assuming 100% deposition. No clinical signs were observed in either species during the 36-day post-exposure observation period. However, lower body weights compared to pre- treatment values were observed in both species. In the second study, rats were exposed by whole body exposure to 0.68 mg/L micronized mometasone furoate powder for 4 hours, and then observed for 3 weeks. Weight loss occurred during the observation period; while rales, ano-genital staining, soft stools and emaciation were the principal clinical observations. At necropsy, several rats had discoloured lungs, small spleens and discoloured brown skin.</p><p>&nbsp;</p><p><em><strong>Multiple-Dose Toxicity</strong></em></p><p>The intranasal irritation potential of mometasone furoate aqueous nasal suspensions were assessed in beagle dogs administered daily doses of up to 4.0 mg/dog for three days, one week or one month. The aqueous nasal suspensions did not induce irritation in the nasal mucosa, and no compound related changes were observed after one month of administration.</p><p>Mometasone furoate aqueous nasal suspension was well tolerated in toxicity studies conducted in rats and dogs for 6 months. Rats received doses of up to 0.600 mg/kg (0.18 mg/day; 70 times the proposed human dose); dogs received doses of up to 0.15 mg/kg (2.0 mg/day; 35 times the proposed human dose). Rats treated with 0.6 mg/kg experienced hair loss on the back during the last 5 weeks, which correlated with hypotrichosis. The no-effect dose for pharmacologic effects in rats was 0.050 mg/kg based on low body weight gains at higher doses. Dogs treated with 0.15 mg/kg demonstrated eosinophil counts, which were lower than pre-test and concurrent controls after 4, 13 and 26 weeks. In addition, ACTH response in the 0.045 and 0.15 mg/kg dose groups was lower than control. These differences were dose-related and were attributed to mometasone furoate. No evidence of nasal irritation was present at any dose in either the rat or the dog study. No target organs of systemic toxicity were identified in either study.</p><p>&nbsp;</p><p>Mometasone furoate aqueous nasal spray was well tolerated when administered intranasally to dogs for one year at doses of up to 2.0 mg/day. In the 2.0 mg/day dose group, an increased incidence of alopecia, minimal decreases in lymphocytes and eosinophils, decreases in basal and post-ACTH cortisol response, lower adrenal gland weights, small or atrophied adrenal glands, epidermal atrophy, minimal splenic lymphoid atrophy, minimal focal epithelial attenuation in the nasal turbinates and retained luminal mucus were observed. &nbsp;&nbsp;&nbsp;&nbsp;Dogs treated with &sup3; 0.2 mg/day demonstrated a dose-related increase in smaller or absent &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;lymphoid aggregates. With the exception of minimally increased retained luminal mucus in the 2.0 mg/day dose group, there was no evidence of irritation or inflammation in the nasal turbinates of mometasone furoate-treated dogs. Thus, the changes in the lymphoid aggregates were considered a localized corticosteroid response associated with application and were not considered to be of toxicologic significance.</p><p>&nbsp;</p><p><em><strong>Mutagenicity</strong></em></p><p>Mometasone furoate was nonmutagenic in the mouse lymphoma assay and the salmonella/mammalian microsome mutagenicity bioassay. Mometasone furoate was negative in the mouse bone marrow erythrocyte micronucleus assay, the rat bone marrow clastogenicity assay, the UDS assay in rat hepatocytes and the mouse mitotic male germ-cell clastogenicity assay, and the Chinese hamster lung cell chromosomal aberrations assay. At cytotoxic doses in Chinese hamster ovary cell cultures, mometasone furoate induced a dose-related increase in simple chromosome aberrations when continuously exposed (7.5 hours) in the nonactivation phase, but not in the presence of rat liver S9 fraction. This finding is not considered to be of significance in the risk assessment of mometasone furoate, since the S9 phase of the chromosomal-aberration assay and all <em>in vivo </em>assays were negative.</p><p>&nbsp;</p><p><em><strong>Carcinogenicity</strong></em></p><p>The carcinogenicity potential of inhaled mometasone furoate (aerosol with CFC propellant and surfactant) at concentrations of 0.25 to 2.0 mcg/L was investigated in 24-month studies in mice and rats. Typical glucocorticoid-related effects, including several non-neoplastic lesions, were observed. No statistically significant dose-response relationship was detected for any of the tumour types. The apparent increase in mouse bladder/seminal vesicle mesenchymal tumours is considered to have no relevance in human carcinogenic risk assessment since it is a species- and strain-specific finding with no human correlate. The greater incidence of pancreatic islet cell hyperplasia in male rats who received 1.0 and 2.0 mcg/L is attributed to the well-established metabolic effects (increased glucose and/or insulin resistance) following prolonged administration of glucocorticoids. Increases in pancreatic islet cell tumours, which are induced by other steroids, reflects a non-genotoxic mechanism operative in an endocrinologically uniquely sensitively species.</p><p>&nbsp;</p><p><em><strong>Reproductive Toxicology</strong></em></p><p>In subcutaneous Segment I and III studies, mometasone furoate was well tolerated at doses up to 7.5 mcg/kg (2.6 times the human dose by inhalation). At 15 mcg/kg, prolonged gestation and prolonged and difficult labour occurred with a reduction in offspring survival and body weight gain or body weight gain. There was no effect on fertility. Like other glucocorticoids, mometasone furoate is a teratogen in rodents and rabbits.</p><p>Teratology studies were conducted in rats, mice and rabbits by the oral, topical (dermal), and/or subcutaneous routes. Umbilical hernia occurred in rats administered &sup3; 600 mcg/kg dermally, cleft palate in mice administered 180 mcg/kg subcutaneously, and gallbladder agenesis, umbilical hernia, and flexed front paws in rabbits administered &sup3; 150 mcg/kg dermally. In these teratogenicity studies, there were also reductions in maternal body weight gains, effects on fetal growth (lower fetal body weight and/or delayed ossification) in rats, rabbits and mice, and reduced offspring survival in mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Benzalkonium Chloride Solution NF/EP (50% w/v)</p></td></tr><tr><td style="vertical-align:top"><p>Citric Acid USP (Monohydrate)</p></td></tr><tr><td style="vertical-align:top"><p>Glycerin USP/Glycerol EP</p></td></tr><tr><td style="vertical-align:top"><p>Microcrystaline Cellulose</p></td></tr><tr><td style="vertical-align:top"><p>CarboxyMethyl Cellulose</p></td></tr><tr><td style="vertical-align:top"><p>Polysorbate 80 NF/EP/BP (Tween 80)</p></td></tr><tr><td style="vertical-align:top"><p>Sodium Citrate (Dihydrate) USP</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water USP/EP</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months before opening.

2 months after first opening of the bottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MASTASONE should be stored below 30&deg;C and protected from light. Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong> 20 mL Bottle</p><p>Bottle: 20 mL White Opaque HDPE Crimp Round Bottle 20mm</p><p>Pump: 100 mcL VP3/93F CS20 Metering Nasal Pump: 20 mm</p><p><strong>Secondary packaging:</strong> Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>